A cGMP Compatible, Non-Viral CAR T Cell Manufacturing Process
Date: Tuesday May 24, 2022
Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST)
Speaker: Andrew Mancini, PhD
Recent breakthroughs in autologous cellular therapies have generated tremendous excitement for the industry; however, these advances have been confronted with the expense of manufacturing of viral gene delivery and concerns over random integration and the safety of viral vectors. To combat these challenges, researchers at the University of California San Francisco have developed a novel system that offers lower toxicity with a single-stranded DNA (ssDNA) approach.
UCSF scientists used MaxCyte ExPERT technology as a non-viral alternative that allows for site-specific delivery of transgenes through homology-directed repair (HDR) to circumvent complex and expensive manufacturing. This approach resulted in highly efficient knock-in integration efficiencies (46-62%) and yields of 1.5 x 109 CAR+ T cells, well above current adoptive cellular therapy doses.
The groundbreaking experiments discussed during this event demonstrate the ability of the MaxCyte GTxTM to deliver ssCTS HDR templates and CRISPR-Cas9 RNP to modify T cells in clinically relevant amounts.
- Outline large-scale, non-viral manufacturing for engineered CAR T cells.
- Demonstrate 5-fold boosted knock-in and >7-fold increased live cell yields relative to dsDNA approaches.
- Reveal MaxCyte GTxTM delivery of ssCTS HDR templates and CRISPR-Cas9 RNP to modify T cells for a future clinical setting.
Andrew Mancini, Ph.D.
Field Application Scientist
Andrew Mancini is a Field Application Scientist at MaxCyte specializing in Cell and Gene Therapy. As a field-based scientist, Andrew works closely with MaxCyte’s partners around the world to develop novel cell engineering workflows for the development of cellular therapeutics. Prior to his time at MaxCyte, Andrew completed his PhD in Biomedical Sciences at the University of California, San Francisco and completed his postdoctoral training at Genentech in Molecular Oncology. He has broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells, and cell lines at both research and manufacturing scales.